Arkolith/Insider Trading/AKBA/Form 4

Malabre Richard C

SVP, Chief Accounting OfficerAkebia Therapeutics, Inc. (AKBA) · full profile →Form 4 · filed Feb 4, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$63K
Net Open-Market Flow
-$63K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 3, 2025Sell(S)30K$2.10$63K280K
Jan 31, 2025Grant(A)85K—$0310K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 31, 2025Grant(A)128K—$0128K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001562180-25-000915) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML